SCHEMBL4669358

SCHEMBL4669358

CCOC(=O)c1ccc(/C=C/c2cc3c(cc2Cc2ccc(F)cc2F)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.49
RARA P10276 8/20 0.47
RARB P10826 8/20 0.47
RARG P13631 5/20 0.47
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
GSK3B P49841 1/20 0.37
BACE1 P56817 1/20 0.37
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
CASP3 P42574 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
HNF4A P41235 1/20 0.36
CYP26A1 O43174 1/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
NFE2L2 Q16236 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669361 1.00 RXRA (0.49) RXRARARARARBRARGRXRB
SCHEMBL4666508 0.88 RARB (0.59) RXRARARARARBRARGRXRB
SCHEMBL4666512 0.88 RARB (0.59) RXRARARARARBRARGRXRB
SCHEMBL10844843 0.85 RARA (0.57) RXRARARARARBRARGRXRB
SCHEMBL10844848 0.85 RARA (0.57) RXRARARARARBRARGRXRB
SCHEMBL14018618 0.83 RXRA (0.44) RXRARARARARBRARGRXRB
SCHEMBL4666520 0.83 RARA (0.50) RXRARARARARBRARGRXRB
SCHEMBL4666519 0.83 RARA (0.50) RXRARARARARBRARGRXRB
SCHEMBL10842832 0.81 RARA (0.52) RXRARARARARBRARGRXRB
SCHEMBL10842823 0.81 RARA (0.52) RXRARARARARBRARGRXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324970-B1 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA HOFFMANN LA ROCHE (CH) 2008-11-05 EP disclosed
EP-1935869-A1 Retinoids for the treatment of emphysema F. HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
US-6777418-B2 FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-08-17 US disclosed
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders SYNTEX (U.S.A.) LLC 2002-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders RXRA, RXRG, RXRB RXRA 1/4885RARA 5/4885RARB 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.